WAVEMAN · COMPANY

LFWD · Lifeward Ltd.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

LFWD

Name: Lifeward Ltd. (LFWD) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Lifeward Ltd.

MEDICAL DEVICES · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES · CIK 0001607962

ACTIVIST 13D☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

-94.5%

XBRL, annual

NET MARGIN

-1422.4%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

4 funds added or opened last quarter

below 98% of Medical Devices

REVENUE

-94.5% year over year

below 98% of Medical Devices

MARGIN

-1422.4% net margin

below 98% of Medical Devices

BUYBACKS

no share repurchases reported

SHORT

4.3% of shares outstanding short · 18.8 days to cover · settled 2026-07-31

more than 58% of Medical Devices

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Oramed Pharmaceuticals Inc. disclosed a 5%+ stake (49.9%) in the last six months.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -4.1%

-4.1%12M

INSIDER SELL13D/G STAKE

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

An activist crossed the 5% line with declared intent.

The record shows 4 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

TMO PEN ROK BLFS MTD SIBN WRBY ISRG TXG DXCM EW TMDX

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Lifeward Ltd. in the period covered. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Lynch Jeannine

VP of Market Access & Strategy

SELL

2025-09-02

1,591.0

$1.0K

Jasinski Lawrence J

Chief Executive Officer

SELL

2025-05-21

1,909.0

$2.4K

Richner Randel

Director

SELL

2024-12-13

4,285.0

$7.2K

Turk Joseph E Jr

Director

BUY

2024-12-13

6,000.0

$10.1K

Swinford Michael

Director

BUY

2024-11-25

21,622.0

$43.9K

17 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 12 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

CITADEL ADVISORS LLC

18,064.0 sh

$141.8K

RENAISSANCE TECHNOLOGIES LLC

11,327.0 sh

$86.8K

UBS Group AG

2,152.0 sh

$16.5K

MORGAN STANLEY

274.0 sh

$2.1K

SBI Securities Co., Ltd.

196.0 sh

$1.5K

5%+ owners

13D = intent to influence · 13G = passive

Oramed Pharmaceuticals Inc.

ACTIVIST 13D · 2026-05-14

49.9%

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Executive pay vs shareholder return · Larry Jasinski

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2024

$473.3K

$278.8K

$367.0K

-80%

—

2023

$888.7K

$860.6K

$532.0K

-37%

—

2022

$854.0K

$642.6K

$471.1K

-38%

—

2021

$927.5K

$848.0K

$431.3K

-7%

—

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$1.4M	$25.7M	$13.9M	$5.5M
GROSS PROFIT	$8.4M	$8.2M	$4.5M	$1.9M
OPERATING INCOME	$-19.7M	$-29.3M	$-23.6M	$-19.1M
NET INCOME	$-19.9M	$-28.9M	$-22.1M	$-19.6M
EPS (DILUTED)	-17.16	-39.96	-31.13	-2.20
OPERATING CASH FLOW	$-16.8M	$-21.7M	$-20.7M	$-17.9M
CASH	$2.2M	$6.7M	$28.1M	$67.9M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE